Vaxart will host a webcast with key opinion leaders to discuss the health impact of norovirus and the disease burden.

Vaxart, Inc.

Vaxart, Inc.

The company provides a detailed description of its norovirus clinical program

The webcast will be held on March 28, 2023 at 1:00 p.m.

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. March 28, 2023 at 1:00 p.m. ET.

The webcast will feature presentations by renowned norovirus experts Jan Vinje, PhD, Director of the National Calicivirus Laboratory, Centers for Disease Control and Prevention, and Sarah Bartsch, Project Director, Public Health Informatics, Computational and Operations Research, Research Foundation. City University of New York.

In addition, Vaxart management will provide details of the company’s investigational norovirus oral vaccine program, including two current Phase 2 clinical trials:

  • An ongoing Phase 2 GI.1 norovirus challenge study measuring the efficacy and safety of our norovirus vaccine candidate. The study was designed to identify a protective association between immune responses to the vaccine and reduced risk of norovirus infection and/or severe gastrointestinal disease. The company expects to report significant data from this study in Q3 2023.

  • A Phase 2 dosing study of Vaxart’s bivalent norovirus oral vaccine candidate was designed to determine the vaccine dose for a Phase 3 clinical trial. The company expects to report significant data from this study in mid-2023.

To register for the website, please click here over here. A replay of the webcast is available on the Company’s website at Following the conclusion of the event.

About KOLs

Jan Vinje, Ph.D.
Dr. Vinje is the head of the National Calicivirus Laboratory and director of CaliciNet at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. Dr. Vinje Ph.D. He joined the CDC in 2006 after receiving a postdoctoral fellowship at the University of Utrecht in the Netherlands in 1999 and an appointment as a research assistant professor at the University of North Carolina at Chapel Hill, where he has served for the past 10 years. On several program advisory committees in several European research projects (FP6, FP7). He serves as a technical expert on the norovirus subcommittee of the National Advisory Committee on Microbiological Food Standards and is a member of the International Virus Taxonomy Study Group. Caliciviridae (chair since 2014) and Astroviridae. He is currently a member of the Editorial Board. Journal of Clinical Microbiology and co-editor of the magazine Food and environmental virologyAnd he serves as one For this Reviewer for several high impact journals. Dr. Vinje has published over 100 peer-reviewed publications and numerous book chapters. His research interests include all viral gastrointestinal diseases, including the identification, detection and prevention of norovirus infections.

Sarah M. Bartsch, MPH
Ms. Bartsch is a project director and senior analyst at the Center for Public Health Informatics, Computation, and Operations Research (PHICOR), Artificial Intelligence, Modeling, and Informatics for Nutrition Guidelines and Systems (AIMINS), and the Center for Advanced Technology and Communications in Health (CATCH), headquartered in New York. York City University (CUNY) Graduate School of Public Health and Health Policy. She has been part of the team since August 2009 and has more than a decade of experience using systems approaches and developing computational and mathematical models to support a wide range of public health decision makers. Bartsch has authored more than 95 scientific publications, including more than 30 as first author.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a variety of oral recombinant vaccines based on a proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and avoid needle stick injuries. Vaxart believes its proprietary pill vaccine delivery platform is ideal for delivering recombinant vaccines, enabling the company to develop currently marketed vaccines orally and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed extensive domestic and international patent applications using proprietary technology and innovations in adenovirus and TLR3 agonists.

Note regarding forward-looking statements
This press release contains forward-looking statements that involve significant risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements regarding Vaxart’s strategy, expectations, plans and objectives, results from preclinical and clinical trials, commercial agreements and licenses, and beliefs and management expectations. These forward-looking statements may be accompanied by words such as “should,” “believe,” “may,” “potential,” “will,” “expect,” “predict,” “plan,” and other words. Same meaning. Examples of such statements include, but are not limited to, statements regarding Vaxart’s ability to develop and commercialize its product candidates, including its vaccine enhancement products. Vaxart’s expectations regarding clinical results and trial data; and Vaxart’s expectations regarding the efficacy of its product candidates. Vaxart may not achieve its plans, achieve its objectives or meet the expectations or projections expressed in forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events may differ materially from the plans, objectives, expectations and projections expressed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements made by Vaxart.

Please see the risks described in the “Risk Factors” section of Vaxart’s quarterly and annual reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements except as required by law.


Investor Relations:

Andrew Blazier

FINN partners

(646) 871-8486

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *